Evidence map›Paper›PMID 39265877›Full record

ArticleThe Journal of allergy and clinical immunology2024

Tissue-specific inducible IL-33 expression elicits features of eosinophilic esophagitis.

Grace C Pyon, Mia Y Masuda, Arina Putikova, Huijun Luo, Jessica B Gibson, Adelyn D Dao, Danna R Ortiz, Piper L Heiligenstein, James J Bonellos, William E LeSuer and 7 more

Abstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Mouse models of eosinophilic esophagitis: molecular and translational insights.American journal of physiology. Gastrointestinal and liver physiology · 2025
    Review
  6. Review
  7. Review
  8. Animal models of eosinophilic esophagitis.Journal of leukocyte biology · 2024
    Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Grace C PyonDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Mia Y MasudaDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic, Rochester, Minn and Mayo Clinic Arizona, Scottsdale, Ariz.
Arina PutikovaDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Huijun LuoDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Jessica B GibsonDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Adelyn D DaoDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Danna R OrtizDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Piper L HeiligensteinDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
James J BonellosDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
William E LeSuerDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz.
Rish K PaiDivision of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, Ariz.
Shipra GargDivision of Laboratory Medicine and Pathology, Phoenix Children's Hospital, Phoenix, Ariz.
Matthew A RankDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Division of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, Ariz.
Hiroshi NakagawaDivision of Digestive and Liver Diseases, Department of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY.
Hirohito KitaDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic, Rochester, Minn and Mayo Clinic Arizona, Scottsdale, Ariz.
Benjamin L WrightDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Division of Allergy and Immunology, Phoenix Children's Hospital, Phoenix, Ariz.
Alfred D DoyleDepartment of Medicine, Division of Allergy, Asthma, and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, Ariz; Department of Immunology, Mayo Clinic, Rochester, Minn and Mayo Clinic Arizona, Scottsdale, Ariz. Electronic address: doyle.alfred@mayo.edu.

Funding

Mechanisms of IL-33 secretion in allergic diseasesR01AI128729 · NIAID · MAYO CLINIC ROCHESTER · PI Hirohito Kita, SCOTT M. O'GRADY · 2017 to 2026
$5.6M
Mechanisms of Allergen-induced Type 2 ImmunityR37AI071106 · NIAID · MAYO CLINIC ROCHESTER · PI Hirohito Kita · 2018 to 2026
$5.2M
Type 2 Innate Lymphoid Cells and AsthmaR01HL117823 · NHLBI · MAYO CLINIC ROCHESTER · PI KITA, HIROHITO · 2014 to 2021
$3.5M
Autophagy and esophageal tissue remodeling in EoER01DK114436 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI NAKAGAWA, HIROSHI · 2017 to 2024
$3.1M
Mechanisms of adverse gastrointestinal events during oral immunotherapyK23AI158813 · NIAID · MAYO CLINIC ARIZONA · PI Benjamin L. Wright · 2022 to 2026
$949k
NHLBI NIH HHS R01 HL117823NIAID NIH HHS K23 AI158813NIAID NIH HHS R01 AI128729NIAID NIH HHS R37 AI071106NIDDK NIH HHS R01 DK114436
6 · The paper itself

Abstract

backgroundIL-33 is a type 2 inflammatory cytokine that is elevated in the esophageal epithelium of eosinophilic esophagitis (EoE) subjects. We previously developed a mouse model of EoE dependent on constitutive overexpression of IL-33 from the esophageal epithelium (EoE33).

objectiveOur objective was to develop an inducible, IL-33-dependent model of EoE and examine induction of EoE-associated pathology.

methodsWe utilized a tetracycline-inducible system to express IL-33 in the esophagus by generating 2 transgenic mice. The first (iSophagus) expresses a reverse tetracycline transactivator from the esophageal epithelium. The second (TRE33) features a tetracycline response element driving expression of IL-33. When crossed, these mice generate an inducible model of EoE (iEoE33). Mice were administered doxycycline-infused chow for up to 2 weeks. Cytokines were assessed by ELISA or bead-based multiplex analysis. T cells were assessed by flow cytometry. Pathology was assessed by histology and immunohistochemistry for IL-33, eosinophil peroxidase, CD4, and Ki-67. iEoE33 was treated with steroids and crossed with IL-13

resultsDoxycycline-treated iEoE33 mice demonstrated expression of IL-33 in the esophageal epithelium, and esophageal pathology including eosinophilia, CD4

conclusionInducible IL-33 expression in the esophageal epithelium elicited features pathognomonic of EoE. iEoE33 enables investigation of EoE disease mechanisms as well as initiation, progression, and resolution.

Indexed as

Disease Models, AnimalEosinophilic EsophagitisInterleukin-33Mice, TransgenicAnimalsEsophageal MucosaEsophagusHumansInterleukin-13MiceMice, KnockoutIl33 protein, mouseInterleukin-13Interleukin-33eosinophileosinophilic esophagitisIL-33transgenetype 2 inflammation

Identifiers

PMID39265877
PMCPMC11625005

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.